# RNDO-564-001 (NCT07218003)

> A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

No report yet. It can be ordered.

- Drugs tested: RNDO-564; RNDO-564 plus pembrolizumab

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07218003
- Phase: PHASE1
- Status: ENROLLING_BY_INVITATION
- Sponsor: Rondo Therapeutics
- Conditions: Non Small Cell Lung Cancer; Cervical Cancer; Head and Neck Squamous Cell Cancer; Triple Negative Breast Cancer (TNBC); Urothelial Carcinoma Bladder; Gastroesophageal Junction (GEJ) Adenocarcinoma; Esophageal Squamous Cell Cancer; Gastric Cancer; Cancer; Solid Tumors (Phase 1)
- Interventions: RNDO-564; Pembrolizumab
- Enrollment: 149
- Primary outcome: All Arms: - Proportion of participants with adverse events (including dose limiting toxicities) as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0
- Primary outcome: Dose Optimization Arms: • Identify one or more recommended Phase 2 doses (RP2D)

## Indexed commentary on RNDO-564-001 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=rndo-564-001-nct07218003
